

Zeiss Surpasses 8 Million Eyes Treated with SMILE Worldwide


[Share](#) | [Copy Link](#)

Zeiss announced that more than 8 million eyes have been treated with Small Incision Lenticule Extraction (SMILE) globally to date. The FDA approved the VisuMax Femtosecond Laser for the SMILE procedure in 2016.

“Zeiss SMILE is a game-changer for laser vision correction that redefines refractive surgery and we are thrilled that SMILE has reached this important milestone,” Dirk Muehlhoff, Head of Refractive Lasers at Zeiss Medical Technology, said in a company news release. “We are excited to see SMILE so widely accepted by doctors and their patients, and to know that SMILE has helped doctors improve vision for so many people around the world.”

SMILE is performed using the VisuMax femtosecond laser which creates a thin disc-shaped lenticule within the cornea for a minimally invasive corneal refractive procedure. The lenticule is then removed through a small incision, thereby achieving the desired vision correction. SMILE requires only one laser to perform the entire solution leaving the outer corneal layer largely intact, thus potentially contributing to the cornea's biomechanical and refractive stability after surgery.

Eyes treated with ZEISS SMILE worldwide



en-001_34_065_006219 © ZEISS 2023. Information refers only to the sales in selected countries. The contents of this document are for informational purposes only and do not constitute an offer of any product or service. Please contact your regional representative for more information. Subject to changes in design and scope of delivery and due to ongoing technical development. SMILE is either a trademark or registered trademark of Carl Zeiss Meditec AG or other companies of the ZEISS Group in Germany and/or other countries. © Carl Zeiss Meditec AG, 2023. All rights reserved.